Preloader

NIPT (Non-Invasive Prenatal Testing Screening Test Screening Test)

Next Generation NIPT Test

NIPT is a non-invasive prenatal screening test performed from a maternal blood sample starting from the 10th week of pregnancy. By analyzing cell-free DNA (cfDNA) originating from the placenta and circulating in the maternal bloodstream, NIPT provides a risk assessment for specific fetal chromosomal abnormalities.

Using whole-genome next-generation sequencing (NGS) technology, NIPT helps assess chromosomal aneuploidies, particularly trisomies of chromosomes 13, 18, and 21. Depending on the test panel, sex chromosome and other autosomal chromosomal abnormalities, as well as selected chromosomal deletions and duplications, may also be evaluated.

NIPT supports the identification of pregnancies at increased risk and helps inform clinical decision-making during pregnancy. The scope of the test and the abnormalities assessed may vary depending on the selected test panel.

NIPT is a screening test, not a diagnostic test. Positive or high-risk results should be clinically evaluated and, when appropriate, confirmed through invasive prenatal tests (see: Prenatal Testing) such as CVS (chorionic villus sampling) or amniocentesis. A negative result does not completely exclude all chromosomal or genetic abnormalities.

For detailed information about available test options and their scope, please contact our center. Test selection is determined based on the clinical characteristics of the pregnancy, ultrasound findings, family history, and the physician’s clinical assessment.

//
Our customer support team is here to answer your questions!